BB Biotech – equity proposition

BB Biotech (BION) is a Swiss-listed investment company managed by Bellevue Asset Management, a specialist in biotech investments. The company provides investors with targeted access to the global biotechnology sector, focusing on innovative companies developing transformative therapies. BION aims to deliver long-term capital growth through active, fundamental stock selection.

Below we highlight four key reasons why BB Biotech represents a compelling investment case:

1. BION has focused access to the global biotechnology sector, a structurally growing industry driven by medical innovation and unmet patient needs.
2. The company is a leading and experienced biotech investor with over three decades of sector expertise and a proven long-term track record.
3. BION has a portfolio centred on high-quality, commercial-stage and late-stage biotechnology companies, supporting cash flow visibility and risk control.
4. The company has an attractive long-term outlook for the biotech sector, supported by scientific progress, improving funding conditions and increased strategic activity.

For further details, please refer to our latest research on BB Biotech.